ACADIA Pharmaceuticals Announces Appointment of Stephen Davis as Executive Vice President, Chief Financial Officer and Chief Business Officer

SAN DIEGO—(BUSINESS WIRE)—Jul. 15, 2014—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in neurological and related centralnervous system disorders, announced the appointment of Stephen Davis asExecutive Vice President, Chief Financial Officer and Chief BusinessOfficer, effective today. Mr. Davis will report to Uli Hacksell, Ph.D.,ACADIA’s Chief Executive Officer.

“Steve is a highly accomplished industry executive with extensivefinancial and operational experience, and will be an outstandingaddition to our team,” said Dr. Hacksell. “Steve’s impressive backgroundand demonstrated leadership skills will be key as we continue to buildthe corporate infrastructure necessary to support the planned launch ofpimavanserin in Parkinson’s disease psychosis and seek to maximize thesignificant opportunities ahead for pimavanserin.”

Mr. Davis brings over 20 years of executive-level experience in thepharmaceutical industry. He most recently served as Executive VicePresident and Chief Operating Officer at Heron Therapeutics, Inc., whichhe joined in 2013. He led core business and finance functions there andwas instrumental in developing and implementing a new corporate strategywith a multi-program portfolio. Previously, Mr. Davis served asExecutive Vice President and Chief Operating Officer at ArdeaBiosciences, Inc. from 2010 to 2013, where he oversaw businessfunctions, including finance, commercial planning, and corporatedevelopment, and played a critical role in building and growing thecompany. Prior to joining Ardea, Mr. Davis served in numerous executiveroles at Neurogen Corporation from 1994 to 2010, including ChiefFinancial Officer, Chief Operating Officer, and Chief Executive Officer,completing multiple collaborations and product acquisitions with globalpharmaceutical companies. Mr. Davis currently serves on the Board ofDirectors of Heron Therapeutics and Synageva BioPharma Corp.

Earlier in his career, Mr. Davis practiced as a Certified PublicAccountant with a major accounting firm and as a corporate andsecurities attorney with a Wall Street law firm. Mr. Davis received hisBachelor of Science degree in Accounting from Southern NazareneUniversity and a J.D. from Vanderbilt University.

“This is an exciting time to join ACADIA as it advances pimavanserintoward an NDA submission, prepares for the planned launch ofpimavanserin, and strategically expands the program into other importantneurological and psychiatric indications,” said Mr. Davis. “I lookforward to being part of a high-caliber team that shares the vision ofbuilding a leading U.S. specialty neurology company.”

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in neurological and related central nervous system disorders.ACADIA has a pipeline of product candidates led by pimavanserin, whichis in Phase III development as a potential first-in-class treatment forParkinson’s disease psychosis. Pimavanserin is also in Phase IIdevelopment for Alzheimer’s disease psychosis and has successfullycompleted a Phase II trial as a co-therapy for schizophrenia. ACADIAalso has clinical-stage programs for chronic pain and glaucoma incollaboration with Allergan, Inc. and two advanced preclinical programsdirected at Parkinson’s disease and other neurological disorders. Allproduct candidates are small molecules that emanate from internaldiscoveries. ACADIA maintains a website at www.acadia-pharm.comto which ACADIA regularly posts copies of its press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress, expansion and timingof ACADIA’s drug discovery and development programs, either alone orwith a partner, including clinical trials, the potential benefits to bederived from ACADIA’s product candidates, in each case includingpimavanserin, any future approval or launch of pimavanserin forParkinson’s disease psychosis or any other indication, any expansion orsignificant opportunities ahead for the pimavanserin program, ACADIA’sgrowth, or the ability of ACADIA to become a leading U.S. specialtyneurology company. These statements are only predictions based oncurrent information and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingthe risks and uncertainties inherent in drug discovery, development andcommercialization, and collaborations with others, and the fact thatpast results of clinical trials may not be indicative of future trialresults. For a discussion of these and other factors, please refer toACADIA’s annual report on Form 10-K for the year ended December 31, 2013as well as ACADIA’s subsequent filings with the Securities and ExchangeCommission. You are cautioned not to place undue reliance on theseforward-looking statements, which speak only as of the date hereof. Thiscaution is made under the safe harbor provisions of the PrivateSecurities Litigation Reform Act of 1995. All forward-looking statementsare qualified in their entirety by this cautionary statement and ACADIAundertakes no obligation to revise or update this press release toreflect events or circumstances after the date hereof, except asrequired by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Uli Hacksell, Ph.D., ChiefExecutive Officer
Lisa Barthelemy, Director of InvestorRelations
(858) 558-2871